利福喷丁与利福平在肺结核治疗中的药效比较及安全性分析

发布时间：2018-01-25 17:10

本文关键词： 利福喷丁利福平肺结核药效比较安全性　出处：《中国现代药物应用》2015年20期 　论文类型：期刊论文

【摘要】：目的分析和研究利福喷丁与利福平在肺结核治疗中的药效比较及安全性。方法肺结核患者86例,按数字随机表法分为利福喷丁组与利福平组,每组43例。利福平组患者采用利福平治疗;利福喷丁组患者采用利福喷丁治疗,将两组患者治疗6个月后的药效及用药不良现象发生情况进行对比。结果两组患者治疗6个月后比较,利福喷丁组痰菌转阴率显著高于利福平组,差异具有统计学意义(P0.05)。两组患者病灶吸收率比较,利福喷丁组显著高于利福平组,差异具有统计学意义(P0.05)。利福喷丁组不良反应发生率明显低于利福平组,差异具有统计学意义(P0.05)。结论利福喷丁与利福平在肺结核治疗中均有一定治疗效果,但相对于利福平来说,利福喷丁效果更显著,且安全性更高,值得推广。
[Abstract]:Objective to analyze and study the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis. Methods 86 patients with pulmonary tuberculosis were randomly divided into rifampicin group and rifampicin group. The patients in rifampicin group were treated with rifampicin. Rifapentine group patients were treated with rifapentine, the two groups of patients after 6 months of treatment and the occurrence of adverse drug use were compared. Results the two groups of patients after 6 months of treatment were compared. The sputum negative rate in rifampicin group was significantly higher than that in rifampicin group, the difference was statistically significant (P 0.05). The lesion absorption rate in rifampicin group was significantly higher than that in rifampicin group. The incidence of adverse reactions in rifampicin group was significantly lower than that in rifampicin group. Conclusion Rifapentine and rifampicin are effective in the treatment of pulmonary tuberculosis, but compared with rifampicin, rifapentine is more effective and safer than rifampicin. It is worth popularizing.
【作者单位】：辽宁省本溪市中心医院;
【分类号】：R521
【正文快照】： 结核病在我国发病率较高,其是由结核分枝杆菌所引发的慢性传染性疾病,可累及多脏器,其中肺部感染最为常见。目前肺结核现已成为较严重公共卫生问题,其不但增加患者痛苦,而且也给社会带来沉重负担,因此,探寻合理、低毒、高效治疗方案已经成为临床医生亟需解决问题。本文选取肺

【参考文献】